Preserving photoreceptor cells following retinal injury: Inhibition of alternate complement pathway revealed

ByConnor Hodde

Retinal detachment can occur as a result of either blunt trauma or as a side effect of a variety of ophthalmic diseases, including diabetic retinopathy, ocular tumors, and age-related macular degeneration.  There is a significant increase in the immune system’s ‘alternative complement pathway’ following retinal detachment, researchers report, adding that this pathway facilitated early photoreceptor cell death after injury. Additionally, by blocking the alternative complement pathway, through both genetic and pharmacologic means, photoreceptors were protected from cell death.

Read the entire article here.

Similar Posts

Retinopathy Prevalence Decreasing in Diabetic Adolescents

ByConnor Hodde

A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage.  http://www.medscape.com/viewarticle/752133

Cell transplant restores sight in mice

ByConnor Hodde

Experimental cell transplants can improve the sight of visually impaired mice, it has been widely reported. The Independent called the research behind the news a “major step towards cure for blindness”, while The Guardian said the work is “the first demonstration that cell transplants can restore useful vision”. During the research, scientists used mice bred…

Why Face Recognition Can Be Difficult with Central Vision Loss

ByConnor Hodde

Diseases such as age-related macular degeneration, cone-rod dystrophy and Stargardt disease cause scotomas, or blind spots, which often have devastating effects on central vision. They cause gaps in a person’s visual field, making it difficult to see words in a book, images on a computer monitor or TV and the features of someone’s face. A…

Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results

ByConnor Hodde

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read the entire…

New Polymer Allows Improved Method for Preparation of Nanoparticles for Drug Delivery

ByConnor Hodde

Ainhoa Lejardi, an engineer at the UPV/EHU, has created a new polymer material which could improve the preparation of nanospheres for their use as a method of controlling the release of pharmaceuticals, research which is currently ongoing at the Consejo Superior de Investigaciones Científicas (CSIC) (Spanish National Research Council) in Madrid. http://www.azonano.com/news.aspx?newsID=24876

Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)

ByConnor Hodde

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. Read the entire article here.